Symbol="XRTX"
AssetType="Common Stock"
Name="XORTX Therapeutics Inc"
Description="XORTX Therapeutics Inc., a biopharmaceutical company, is dedicated to the development and commercialization of therapies to treat progressive kidney disease, hypertension, insulin resistance, and diabetic nephropathy. The company is headquartered in Vancouver, Canada."
CIK="1729214"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="SUITE 2400 - 745 THURLOW STREET, VANCOUVER, BC, CA"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="14391800"
EBITDA="-7893947"
PERatio="None"
PEGRatio="None"
BookValue="0.504"
DividendPerShare="0"
DividendYield="0"
EPS="-0.44"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.407"
ReturnOnEquityTTM="-0.62"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.44"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="6.15"
TrailingPE="-"
ForwardPE="0.962"
PriceToSalesRatioTTM="-"
PriceToBookRatio="1.485"
EVToRevenue="-"
EVToEBITDA="-0.355"
Beta="0.189"
num_52WeekHigh="1.94"
num_52WeekLow="0.41"
num_50DayMovingAverage="0.682"
num_200DayMovingAverage="0.714"
SharesOutstanding="17989700"
DividendDate="None"
ExDividendDate="None"
symbol="XRTX"
open="0.82"
high="0.82"
low="0.74"
price="0.74"
volume="169031.00"
latest_trading_day="2023-07-27"
previous_close="0.80"
change="-0.06"
change_percent="-7.8750%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="45"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="55"
Volume_recent_avg="72236"
Change_recent_avg="0.01"
Delta_recent_avg="0.06"
Variance_recent_avg="0.03"
Change_ratio_recent_avg="-0.69"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="55"
Aroon_momentum_negative="45"
image_negative_thumbnail_id_1="1146"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0179.jpeg"
image_negative_thumbnail_id_2="116"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0060.jpeg"
image_neutral_thumbnail_id_1="524"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0075.jpeg"
image_neutral_thumbnail_id_2="584"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0015.jpeg"
image_positive_thumbnail_id_1="966"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0128.jpeg"
image_positive_thumbnail_id_2="963"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0125.jpeg"
image_professor_thumbnail_id_1="1200"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0034.jpeg"
image_professor_thumbnail_id_2="1168"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0002.jpeg"
